[1] LATGE J P, CHAMILOS G. Aspergillus fumigatus and aspergillosis in 2019[J]. Clin Microbiol Rev, 2019, 33(1): e00140-18. [2] SHI J Y, XU Y C, SHI Y, et al. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin[J]. Chin Med J (Engl), 2010, 123(19): 2706-2709. [3] WANG H C, HSIEH M I, CHOI P C, et al. Comparison of the Sensititre YeastOne and CLSI M38-A2 microdilution methods in determining the activity of amphotericin B, itraconazole, voriconazole, and posaconazole against Aspergillus species[J]. J Clin Microbiol, 2018, 56(10): 1-6. [4] DUDAKOVA A, SPIESS B, TANGWATTANACHULEEPORN M, et al. Molecular tools for the detection and deduction of azole antifungal drug resistance phenotypes in Aspergillus species[J]. Clin Microbiol Rev, 2017, 30(4): 1065-1091. [5] WANG D Y, GRICOURT M, ARNE P, et al. Mutations in the Cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus isolated from avian farms in France and China[J]. Poult Sci, 2014, 93(1): 12-15. [6] MELLADO E, GARCIA-EFFRON G, ALCAZAR-FUOLI L, et al. Substitutions at methionine 220 in the 14 alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs[J]. Antimicrob Agents Chemother, 2004, 48(7): 2747-2750. [7] WHITE P L, POSSO R B, BARNES R A. Analytical and clinical evaluation of the PathoNostics AsperGenius assay for detection of invasive aspergillosis and resistance to azole antifungal drugs during testing of serum samples[J]. J Clin Microbiol, 2015, 53(7): 2115-2121. [8] CAMPS S M, VAN DER LINDEN J W, LI Y, et al. Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature[J]. Antimicrob Agents Chemother, 2012, 56(1): 10-16. [9] RESENDIZ SHARPE A, LAGROU K, MEIS J F, et al. Triazole resistance surveillance in Aspergillus fumigatus[J]. Med Mycol, 2018, 56(suppl 1): 83-92. [10] DENG S, ZHANG L, JI Y, et al. Triazole phenotypes and genotypic characterization of clinical Aspergillus fumigatus isolates in China [J]. Emerg Microbes Infect, 2017, 6(12): e109. [11] 冀燕芬, 张莉莉, 邓淑文, 等. 烟曲霉临床菌株对体外抗真菌药物的敏感性研究[J]. 同济大学学报(医学版), 2017, 38(1): 74-79. [12] 张莉莉, 王强兄, 沈亮亮, 等. 曲霉菌临床分离株的分子鉴定及体外抗真菌药物敏感性分析[J]. 同济大学学报(医学版), 2018, 39(1): 70-75. [13] ULLMANN A J, AGUADO J M, ARIKAN-AKDAGLI S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline[J]. 2018, 24(Suppl 1):e1-e38. [14] VERWEIJ P E, ZHANG J, DEBETS A J M, et al. In-host adaptation and acquired triazole resistance in Aspergillus fumigatus: a dilemma for clinical management[J]. Lancet Infect Dis, 2016, 16(11): e251-e60. [15] BADDLEY J W, MARR K A, ANDES D R, et al. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network[J]. J Clin Microbiol, 2009, 47(10): 3271-3275. |